SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebiuss Q3 results sparked a sharp, volatile reaction: despite a strong reported quarter, traders focused on higher planned capital spending and delayed capacity and revenue milestones, raising concerns about funding needs and potential dilution. Bulls argued that strong AI-cloud demand, customer prepayments and the longer-term outlook supported the business, while some also blamed broader pressure from Nvidia-related headlines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of Nvidia board discussions about potentially removing Jensen Huang, amid allegations involving a company executive and a suspected Chinese spy, have driven concern about leadership continuity and national-security scrutiny. Traders are divided between fearing a CEO transition and further fallout, and viewing the selloff as a buying opportunity because Nvidias AI business remains strong.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas reported Q3 revenue beat and raised outlook are driving attention, with traders highlighting its large backlog and earlier profitability target. Bulls are calling for a short squeeze, while skeptics point to weaker margins, a wider adjusted EBITDA loss, and falling cash reserves.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines stronger-than-expected Q3 results, including positive free cash flow and a record backlog, are driving attention, with traders also citing the companys revenue outlook. Many see the report as a potential turnaround, while skeptics point to ongoing losses, dilution concerns and the stocks history of giving back gains.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the FDAs Nov. 22 decision on Capricors deramiocel for Duchenne muscular dystrophy, with the application now centered on preserving upper-limb function. The recent rally has fueled approval and short-squeeze speculation, while skeptics point to the earlier advisory committee vote and warn that the outcome remains uncertain.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A strong quarterly report and raised outlook sparked a sharp rally, but traders then focused on reports of turmoil around Nvidia CEO Jensen Huang and whether it could affect CoreWeaves ties to Nvidia. Bulls say AI demand and contracted backlog remain intact, while bears point to heavy debt costs and potential dilution as risks that the earnings momentum may not resolve.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention after Q3 results showed sharply higher year-over-year revenue but missed analyst expectations. Traders are split between optimism about its AI-cloud backlog and project financing and concern that contracts have yet to translate into sustained revenue and profitability.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is driving concern about passive-fund selling and weaker institutional demand; traders also point to Bitcoins decline as pressure on the stock. Bearish voices expect further downside, while bulls argue the index news is priced in and Bitcoins direction matters more.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERocks quarterly results are drawing attention, with traders highlighting a return to profitability, strong revenue growth, and reaffirmed full-year guidance alongside a larger backlog tied to AI data-center power demand. Many see the report as bullish and speculate that high short interest could amplify a move, while others remain cautious about execution and volatile price action.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedixs quarterly results drew attention, but managements decision to defer 2027 DefenCath revenue guidance amid uncertainty around CMS reimbursement, utilization and Medicare Advantage is the central concern. Traders are weighing that unclear outlook against stronger-than-expected results and the Heron acquisitions potential to diversify revenue, with reactions split between optimism about the broader portfolio and concern about DefenCaths reimbursement outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive YearPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid...

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumPR NewswireNEW YORK, Nov. 4, 2026 NEW YORK, Nov. 4, 2026 /PRNewswire...

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard Study

Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard Study Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard StudyPR NewswireNEW YORK, Nov. 3, 2026 Largest peer-reviewed study of nonendoscopic esophageal precancer testing to...

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026

PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026PR NewswireNEW YORK, Oct. 30, 2026 Conference Call and Webcast at 8:30 AM ETNEW YORK, Oct. 30, 2026...

Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026

Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026PR NewswireNEW YORK, Oct. 29, 2026 Conference Call and Webcast at 8:30 AM ETNEW...

Cancer-Screening Test Developer Jumps 28% as Medicare Payments Begin

Confirmation that Medicare is now paying for a cancer-screening test sent its developer sharply higher on Friday.&nbsp;Lucid Diagnostics Inc. (NASDAQ: LUCD), a New York cancer-prevention diagnostics company and subsidiary of medical technology company PAVmed Inc. (NASDAQ: PAVM), said it has begun receiving Medicare payments for its EsoGuard Esophageal DNA Test. The company also closed a $15.0M private placement of Series C convertible preferred stock with existing long-term shareholders on October 21.Recall, Lucid said on September 22 that it would begin submitting Medicare claims for ...

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million Financing

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million Financing Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard and Closes $15 Million FinancingPR NewswireNEW YORK, Oct. 22, 2026 Lucid is now submitting Medicare claims and receiving...

Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding Pathways

Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding Pathways Lucid Diagnostics Advances Multiple EsoGuard and EsoCheck Payment, Billing and Coding PathwaysPR NewswireNEW YORK, Sept. 22, 2026 Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill...

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom...

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing.</li><li>The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.</li><li>Trading in PAVM shares was halted at 09:58 ET.</li></ul>Shares of PAVmed Inc. (PAVM) jumped more than 250% on Wednesday morning after its subsidiary, Lucid Diagnostics Inc. (LUCD), won a contract from the U.S. Department of Veterans Affairs (VA) to supply its EsoGuard Esophageal DNA Test for detecting esophageal precancer across the VA healthcare system.The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.<a href="https://stocktwits.com/symbol/PAVM">PAVM</a> was among the top trending tickers on Stocktwits at the time of writing. <a href="https://stocktwits.com/symbol/LUCD">LUCD</a> shares jumped 23% to their highest levels since May 2025.<h2 class="st-heading-2">Contract Details</h2>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing that aligns with the Medicare reimbursement rate set by the Centers for Medicare &amp; Medicaid Services. This structure allows VA hospitals and clinics nationwide to procure EsoGuard through a single, standardized framework.“The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard,” said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics.&nbsp;&nbsp;Lucid Diagnostics focuses on early cancer prevention diagnostics, particularly for patients with gastroesophageal reflux disease who face an elevated risk of developing esophageal precancer and cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for PAVM on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/PAVMED_jpg_a10dfa8673.webp" alt="PAVMED.jpg" width="925" height="96"><figcaption>PAVM's Sentiment Meter and Message Volumes at 10:20 a.m. ET on Jan. 21, 2026 | Source: Stocktwits</figcaption></figure>Sentiment for LUCD changed to ‘bullish’ from ‘neutral’ a day earlier, while message volumes were ‘extremely high’.One user believes the news has ‘real value’.<stembedurl>https://stocktwits.com/pow7904/message/642397455</stembedurl>PAVmed implemented a 1-for-30 reverse stock split on January 2.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gold-rises-to-record-highs-as-investors-seek-out-safe-haven-assets/cmUDMEjR4fK">Gold Jumps To All-Time Highs – Veteran trader Peter Brandt Says $8,000 An Ounce Is On The Cards</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PAVM Stock - The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

iShares Micro-Cap ETF

Lucid Diagnostics Inc

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.61
Prev Close	$1.56
Open	$1.51
Dividend Yield	0.00%
50-Day Moving Average	$3.02
Beta	1.01
Avg. Volume	20,277.89
PE Ratio	-0.10

52-Week High	$28.44
52-Week Low	$1.17
Market Capitalization	$12.83M
EPS (Annual)	-$5.63
Price to Book	0.32
Revenue Per Employee	$1,731.71

Feed

News

Sentiment

Earnings

Fundamentals

Info

PAVM Fundamentals